Company news

Avacta Group PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Result of General Meeting

March 18, 2024

Avacta Announces AVA6000 Poster at AACR

March 6, 2024

Result of REX Retail Offer

March 5, 2024

Result of Placing

February 29, 2024

Proposed REX Retail Offer

February 28, 2024

Proposed Fundraise to progress Therapeutics

February 28, 2024

Share Incentive Plan/Issue of Equity

February 16, 2024

Appointment of Christina Coughlin

January 19, 2024

Appointment of Chief Business Officer

December 19, 2023

ALS-6000-101 Phase 1a Study Data

December 13, 2023

Shareholder update to review AVA6000 Phase 1a data

December 4, 2023

Avacta to present at AACR-NCI-EORTC conference

October 5, 2023

Director/PDMR Shareholding

September 29, 2023

Interim Results for the Period Ending 30 June 2023

September 28, 2023

Peel Hunt Appointed as Joint Broker

September 20, 2023

Appointment Dr.Christina Coughlin as a consultant

September 20, 2023

Successful Completion of Sixth Dose Escalation

September 19, 2023

Result of Annual General Meeting

June 28, 2023

Annual General Meeting and Shareholder Event

June 28, 2023

Completion of Fifth Dose Escalation in AVA6000

June 21, 2023

Director Appointment

June 19, 2023

Statement regarding market speculation

June 19, 2023

AGM and Shareholder Event Detailed Agenda

June 8, 2023

Second Milestone in AffyXell Joint Venture

June 5, 2023

Avacta acquires Coris Bioconcept

June 1, 2023

First Patient Dosed in the US in AVA6000 Phase 1

April 27, 2023

Preliminary Results

April 25, 2023

AVA3996 data poster presented at AACR

April 17, 2023

1st US Clinical Investigator AVA6000 Sites Opened

April 6, 2023

First Patient Dosed in Fifth Cohort of AVA6000

April 5, 2023

Notice of Results and Investor Presentation

April 3, 2023

AVA3996 data poster presentation at AACR

March 27, 2023

Statement re: Silicon Valley Bank

March 13, 2023

Avacta Therapeutics Division Science Day

February 23, 2023

Second Price Monitoring Extn

January 17, 2023

Price Monitoring Extension

January 17, 2023

Successful Completion of Fourth Dose Escalation

January 17, 2023

Avacta to Host Therapeutics Division Science Day

December 19, 2022

Result of the Open Offer

November 8, 2022

Avacta to Present at Theranostics FAP Summit

October 31, 2022

Admission of the Company's Ordinary Shares

October 20, 2022

Posting of the Company's Open Offer Circular

October 20, 2022

Private CB and ABB Launch

October 18, 2022

Proposed acquisition of Launch Diagnostics

October 18, 2022

Interim Results for the Period Ended 30 June 2022

September 29, 2022

AVA6000 receives Orphan Drug Designation from FDA

September 5, 2022

Phase I study of AVA6000 advances to fourth cohort

September 1, 2022

AffyXell successfully completes funding round

July 21, 2022

LG Chem renews license triggers payment to Avacta

June 30, 2022

Second dose escalation in phase 1 trial of AVA6000

June 29, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 18 decks. Every deck is listed under its year.